Active Biotech receives 5 MSEK from VINNOVA


The funds will be used within a pre-clinical project for the development of a new generation of pharmaceuticals for the treatment of autoimmune/inflammatory diseases. The project is partly performed in collaboration with scientists at Lund University.
Lund 21 November 2006
Sven Andréasson
President & CEO
Active Biotech AB
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication renal cancer. Further key projects comprise the three orally administered compounds in clinical development, TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA as well as the I-3D project in pre-clinical co-development with Chelsea Therapeutics.
Active Biotech AB
Box 724, 220 07 Lund
Tel +46 (0) 46-19 20 00
Fax +46 (0) 46-19 20 50